HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G management changes

This article was originally published in The Rose Sheet

Executive Summary

Cosmetics VP Marc Pritchard promoted to VP-global cosmetics and personal care, assuming responsibility for global personal cleansing, deodorants in addition to existing responsibility for Cover Girl and Max Factor, Procter & Gamble announces. Appointment is effective July 1. Paolo de Cesare, currently VP-Northeast Asia skin care and cosmetics, appointed VP-global prestige beauty and skin care, taking on responsibility for P&G's global fine fragrances and mass skin care brands, including Olay, while continuing to oversee SKII brand. Execs will report to President-Global Personal Beauty Care Susan Arnold, who will assume added leadership of global feminine care business...

You may also be interested in...

P&G names four presidents

VPs Marc Pritchard and Paolo de Cesare promoted to president of their respective divisions in recognition of their strong leadership contribution, P&G announces July 25. Pritchard oversees global cosmetics and personal care, while de Cesare directs global prestige beauty and skin care. Two additional execs also were promoted to president from current VP roles - Michael Kehoe, who oversees global oral care, and Martin Riant, who heads global feminine care. Presidential posts are new positions that will be effective Sept. 1. Pritchard and de Cesare were appointed to their current roles last year (1"The Rose Sheet" April 29, 2002, In Brief)...

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts